Cocrystal Pharma doses last subject in Phase 1b norovirus study
Cocrystal Pharma said the last subject was dosed in its Phase 1b norovirus challenge study of CDI-988, with preliminary efficacy results expected late 2026 or early 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
COCP doses last subject in Phase 1b CDI-988 norovirus challenge
Cocrystal Pharma said it dosed the last subject in its Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment.